The North America generic injectables market was valued at USD 35.51 Billion in 2025, driven by the increasing prevalence of chronic diseases and the rising approval of generic injectables in the region. The market is expected to grow at a CAGR of 7.60% during the forecast period of 2026-2035, reaching a value of USD 73.87 Billion by 2035.
Base Year
Historical Period
Forecast Period
The American Cancer Society’s annual cancer statistics report estimated that new cancer cases will surpass 2 million in the United States in 2024. The increasing burden of cancer and other chronic diseases along with the growing geriatric population are a significant growth driver for this market.
One of the major North America generic injectables market trends is the surge in drug approvals of generic injectables by the health regulatory bodies. For instance, in May 2024, the FDA approved Gland Pharma Limited’s generic Edaravone injection indicated for amyotrophic lateral sclerosis.
Several branded injectables are facing patent expiration which allows the entry of generic versions. The market share is also influenced by the rising advancements in the manufacturing processes of generic injectables.
Compound Annual Growth Rate
7.6%
Value in USD Billion
2026-2035
*this image is indicative*
Generic injectables are drugs that are administered generally through intramuscular or intravenous routes. They are manufactured to meet the safety and efficacy profile of the brand-name drugs. Generic injectables are comparatively cheaper and are widely used by patients who need injections frequently. Several branded injectables are facing patent expiration which allows the entry of generic versions, contributing to the expansion of the global generic injectables market. Moreover, the rising advancements in the manufacturing processes of these generic drugs such as lyophilization and aseptic processing are enabling generic manufacturers to produce high-quality products, thereby driving the North America generic injectables market growth.
Injectable drugs are known for their faster therapeutic effects as compared to oral drugs due to their higher bioavailability and thus are highly critical for emergency situations. The increasing burden of chronic diseases along with the growing geriatric population are a significant growth driver for this market. The American Cancer Society’s annual cancer statistics report released in January 2024 estimated that new cancer cases will surpass 2 million in the United States in 2024, which translates to around 5,500 cancer diagnoses in a single day. The increasing prevalence of such diseases will fuel the need for effective medications including injectables, which are poised to augment the North America generic injectables market demand.
One of the major market trends is the surge in drug approvals of generic injectables by the health regulatory bodies. For instance, in May 2024, Indian-based generic injectable manufacturer Gland Pharma Limited announced the approval for its generic Edaravone injection of strengths 30mg/100ml and 60mg/100ml single-dose bags indicated for amyotrophic lateral sclerosis from the United States Food and Drug Administration (FDA). The injectable product, expected to be launched in 2025, is a generic equivalent of Mitsubishi Tanabe Pharma Corporation’s Radicava injection, 30 mg/100 ml and 60 mg/100 ml. The rising introduction of such high-quality generic injectables, supported by the presence of a favorable regulatory environment, is anticipated to boost the market share.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Market Breakup by Container Type
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
The global pharmaceutical giant Pfizer has a strong presence in the market through its subsidiary, Hospira. Hospira specializes in injectable drugs and infusion technologies and was acquired by Pfizer in 2015.
Headquartered in Israel, Teva is one of the largest generic drug manufacturers in the world. The company is leveraging strategic acquisitions and its considerable manufacturing capacity to expand its presence in the generic injectables market.
Baxter International Inc. is a global leader in generic injectables, primarily serving areas such as anesthesia and critical care.
Novartis Pharmaceuticals Corporation, through its spin-off Sandoz, is a key player in the generic injectables market, focusing on therapeutic areas such as oncology, immunology, and endocrinology.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Fresenius SE & Co. KGaA, Endo, Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Viatris Inc. (Mylan N.V.), Biocon, Sanofi, Lupin, and Aurobindo Pharma Limited, among others.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
North America Generic Injectables Companies
United States Generic Injectables Market
Asia Pacific Generic Injectables Market
Europe Generic Injectables Market
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 35.51 Billion in 2025 driven by the rising prevalence of chronic diseases in the region.
The market is anticipated to grow at a CAGR of 7.60% during the forecast period of 2026-2035, likely to reach a market value of USD 73.87 Billion by 2035.
The increasing healthcare needs and the growing geriatric population are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals of generic injectables. For instance, in May 2024, the FDA approved Gland Pharma Limited’s generic Edaravone injection indicated for amyotrophic lateral sclerosis.
Based on the product type, the market is broadly segmented into large molecule injectables and small molecule injectables. Large molecule injectables are divided into monoclonal antibodies (mAbs), and insulin among others)
Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others.
Major applications of the generic injectables include oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others.
The market breakup by route of administration includes intravenous, intramuscular, and subcutaneous, among others.
Distribution channels of the market are hospitals and retail pharmacies, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter, Novartis Pharmaceuticals Corporation, Fresenius SE & Co. KGaA, Endo, Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Viatris Inc. (Mylan N.V.), Biocon, Sanofi, Lupin, and Aurobindo Pharma Limited.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Container Type |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share